Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
February 15, 2024 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023 15:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
September 11, 2023 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate
April 20, 2023 16:06 ET
|
Elucida Oncology, Inc
Clinical data presented at the AACR meeting supports a differentiated safety profile for ELU001 in patients with solid tumorsNo evidence of interstitial lung disease, peripheral neuropathy, liver,...
Elucida Oncology to Present New Clinical and Preclinical Data at the 2023 AACR Annual Meeting
April 11, 2023 16:29 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that two...
Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference
November 03, 2022 09:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...